New hospital medicines, without price agreements, may be temporarily excluded from the basic package due to high prices. Zorginstituut advises on inclusion, and the minister negotiates prices with the manufacturer. Zorginstituut uses data from Medicines Horizon Scan to recommend medicines for the sluice, which is for high-cost treatments in medical-specialist care within hospitals.
These medicines are still in the approval process. These medicines are included in the sluice candidate letter.
| Active substance | Expected Registration | Indication |
|---|---|---|
| Apitegromab | March 2026 | Add on for patients ≥2 years old, who were previously diagnosed with later-onset spinal muscular atrophy (SMA) (i.e., Type 2 and Type 3 SMA) and are receiving an approved survival motor neuron (SMN) upregulator therapy (i.e., either nusinersen or risdiplam). |
| Aumolertinib (mesilate) | February 2026 | EGFR-mutated non–small cell lung cancer (NSCLC) and locally advanced or metastatic EGFR T790M mutation–positive NSCLC. |
| Lonapegsomatropine | July 2026 | Lonapegsomatropin monotherapy for treatment of adult-onset Growth hormone deficiency in adults over 23 years of age and elderly. |
| Lurbinectedin | August 2027 | Lurbinectedin monotherapy for second line treatment of relapsed Small cell lung cancer in adults and elderly who failed one prior platinum-containing chemotherapy, with or without anti-PD-1 or anti-PD-L1 agents. |
| Lurbinectedin | July 2026 | Zepzelca, in combination with atezolizumab, is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide. |
| Nadofaragene firadenovec | March 2026 | Treatment of adult patients with high-grade (HG), Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC). |
| Niraparib / abirateron | May 2026 | In combinatie met predniso(lo)n en ADT voor de behandeling van mannen met mHSPC en afwijkingen in genen betrokken bij het herstel van DNA via homologe recombinatie (HRR+ mHSPC). |
| Nogapendekin Alfa Inbakicept | February 2027 | Nogapendekin alfa inbakicept in combination with pembrolizumab, carboplatin and nab-paclitaxel for first line treatment of advanced or metastatic, stage 3 or 4 Non-small cell lung cancer in adults and elderly. |
| Nogapendekin alfa inbakicept | February 2026 | Nogapendekin alfa in combination with bacillus calmette-guerin for third line treatment of BCG-unresponsive high-grade non-muscle invasive bladder cancer in adults and elderly with carcinoma in situ with or without papillary tumors. |
| Sasanlimab | June 2026 | Sasanlimab, in combination with Bacillus Calmette-Guerin (BCG), for the treatment of patients with BCG-naïve, high-risk, non-muscle invasive bladder cancer (NMIBC). |
| Tafasitamab | January 2026 | Minjuvi is indicated in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) (Grade 1-3a) after at least one line of systemic therapy. |
| Teplizumab | January 2026 | Teizeild is indicated to delay the onset of stage 3 type 1 diabetes in adult and paediatric patients 8 years of age and older with stage 2 T1D. |
Medicines that are included in the sluice are subject to negotiation between the minister and the manufacturer. Once the medicine is out of the sluice, it is clear whether and at what price the medicine will be reimbursed.
These medicines were still in the sluice in the previous scan. Meanwhile, an agreement has been reached with the manufacturer, it is included in the basic insurance and is registered or reimbursed.